Literature DB >> 17214072

Neuroleptic malignant syndrome: a review and report of six cases.

Duangjai Kasantikul1, Buranee Kanchanatawan.   

Abstract

The typical symptoms and signs of neuroleptic malignant syndrome (NMS) consist of fever muscle rigidity (stiffness, myoclonus, rod-like), alterations of consciousness (confusion, agitation, aggression, or catatonia), autonomic nervous system disturbances (i.e., hypertension, tachycardia, tachypnea, profuse sweating, and urine incontinence), abnormal blood tests such as low serum electrolytes, elevated serum creatinine phosphokinase (CPK) level, and leukocytosis. Muscle rigidity is often associated with myonecrosis, myoglobinuria, and elevated serum CPK. The mortality among NMS cases is in the 10 to 70% range depending on the severity of the symptoms and time of therapeutic approach. Mandatory therapy should include removal of causative agents, correction of body fluid and electrolytes, administration of benzodiazepine, clonazepam and bromocriptine (dopamine agonist), proved life-saving medications. The authors reported herein six cases with unusual clinical features of NMS. Four of them had been on antipsychotic for a year before becoming anorexic, dehydrated, agitated, and violent with paranoid delusion. One instance with underlying delirium tremens developed NMS after receiving haloperidol (30 mg IV) in addition to diazepam (200 mg IV) within 24 hours. Another patient was found to suffer from severe NMS after receiving bupropion (Dopamine inhibitor antidepressant) 300 mg/day. All patients displayed cardinal signs and symptoms of NMS in addition to dehydration and pallor. They were treated in the psychiatric ward and recovered rapidly from NMS after receiving clonazepam and bromocriptine and removal of the offending agents.

Entities:  

Mesh:

Year:  2006        PMID: 17214072

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  5 in total

Review 1.  [Neuroleptic malignant syndrome].

Authors:  R Knorr; J Schöllkopf; E Haen
Journal:  Nervenarzt       Date:  2018-03       Impact factor: 1.214

2.  Case reports of neuroleptic malignant syndrome in context of quetiapine use.

Authors:  Mark B Detweiler; Kelly Sullivan; Taral R Sharma; Kye Y Kim; Jonna G Detweiler
Journal:  Psychiatr Q       Date:  2013-12

3.  A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality.

Authors:  Aynur Sahin; Mustafa Cicek; Ozgen Gonenc Cekic; Mucahit Gunaydin; Demet Saglam Aykut; Ozgur Tatli; Yunus Karaca; Mualla Aylin Arici
Journal:  Turk J Emerg Med       Date:  2017-11-27

4.  Neuroleptic malignant syndrome: a case responding to electroconvulsive therapy plus bupropion.

Authors:  Quintí Foguet-Boreu; Montse Coll-Negre; Montse Serra-Millàs; Miquel Cavalleria-Verdaguer
Journal:  Clin Pract       Date:  2018-01-26

5.  Afebrile Neuroleptic Malignant Syndrome associated with Fluphenazine decanoate: A case report.

Authors:  Marzieh Assareh; Laleh Koohi Habibi
Journal:  Iran J Psychiatry       Date:  2010
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.